CRISPR Therapeutics AG is in the healthcare sector and trades as part of the biotechnology industry. CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.



Previous Intraday Performance:

The CRSP shares had a previous change of -2.94% which opened at 38.40 and closed at 37.69. It moved to an intraday high of 38.45 and a low of 37.52.

SeekingAlpha:  3 Gene Therapy Stocks For A Biotech Portfolio

Historical Performance:

Over the last five trading days, CRSP shares returned 0.19% and in the past 30 trading days it returned -2.53%. Over three months, it changed 17.82%. In one year it has changed -41.66% and within that year its 52 week high was 73.90 and its 52 week low was 22.22. CRSP stock is 69.62% above its 52 week low.

Our calculations result in a 200 day moving average of 38.63 and a 50 day moving average of 38.18. Right now, CRSP stock is trading -2.43% below its 200 day moving average and may be a great opportunity to buy, but should check other technical indicators to confirm a buy signal.

SeekingAlpha:  3 Gene Therapy Stocks For A Biotech Portfolio

Liquidity:

The company has a market cap of $2.0b with 52.9m shares outstanding and a float of 51.1m shares. Trading volume was 276,842 shares and has experienced an average volume of 554,480 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for CRISPR Therapeutics AG was -1.71 which ended on 31st of December 2018. Based on 3 analyst estimates, the consensus EPS for the next quarter is -0.88.

Below was the last reported quarterly diluted earnings per share:

1stQtr 2019Reported 04-29-2019: -0.93
4thQtr 2018Reported 02-25-2019: -0.92
3rdQtr 2018Reported 11-07-2018: -1.07
2ndQtr 2018Reported 08-07-2018: -0.82
1stQtr 2018 -0.62

The growth of the EPS is critical in understanding the current valuation of CRISPR Therapeutics AG; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -95.60% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 52.80% of institutional ownership.



The beta was calculated to be 3.04.

Business Wire:  City of New York Executes Lease with Clipper Realty Inc. for Renewal of Commercial Leases at 250 Livingston Street Property

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -55.24%, return on assets is -42.44%, price-to-sales is 981.13 and price-to-book is 5.41.

Company Score Card:

Results are out of six:
 2  : Growth Expectations Result
 5  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here